Major Players Operating in the Global Osteoporosis Drugs Market from 2019 to 2023 | Technavio
LONDON--(BUSINESS WIRE)--Jul 31, 2019--
Vendors in the market are increasingly focusing on the adoption of more targeted approaches such as anabolic medications for the effective treatment of the disease. Anabolic medications improve bone quality and increase its mass, promote new bone formation, and reduce fracture incidence. Thus, the approval of such drugs and the presence of favorable drug pipeline will fuel the growth of the osteoporosis drugs market during the forecast period. Furthermore, this industry research report also presents a competitive analysis of the market by geography (North America, Europe, Asia, and ROW), and product (antiresorptive drugs and anabolic drugs).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190731005453/en/
Technavio has announced its latest market research report titled global osteoporosis drugs market 2019-2023. (Graphic: Business Wire)
Competitive vendor landscape
The global osteoporosis drugs market is highly competitive with major vendors such as Amgen Inc., Eli Lilly and Company, Novartis AG, Pfizer Inc., and Radius Health, Inc, competing on the basis of price, quality, and market presence.
“The growing need to provide patients with a new route of administration for effective drug delivery has led to the emergence of the transdermal drug delivery system. These systems ensure the availability of drugs to the targeted site for prolonged action. Thus, the development of transdermal drug delivery system will fuel the growth of the osteoporosis drugs market during the forecast period,” says a senior analyst at Technavio.
Top five osteoporosis drugs market vendors
Amgen Inc. is engaged in the development of products in the areas of oncology/hematology, cardiovascular, neuroscience, inflammation, bone health, and biosimilars. The key offerings of the company include Prolia, a human monoclonal antibody used for the treatment of osteoporosis, and EVENITY, which reduces the risk of fractures and increases bone mineral density in men and postmenopausal women with osteoporosis.
Eli Lilly and Company
Eli Lilly and Company owns and operates businesses under two segments: human pharmaceutical products, and animal health products. The company’s key offerings in the osteoporosis drugs market include FORTEO and Evista.
Novartis AG develops innovative medicines under two business units, namely Novartis Pharmaceuticals and Novartis Oncology. Novartis Pharmaceuticals offers patented treatments in the areas of ophthalmology, immunology, dermatology, neuroscience, respiratory, and cardiometabolic. Under its osteoporosis drugs category, the company offers ZOMETA, Reclast, and Miacalcin.
Pfizer Inc. operates two segments, namely innovative health and essential health. The company offers two drugs for the treatment of osteoporosis, which includes Viviant, a selective estrogen receptor modulator used to treat osteoporosis, and PREMARIN, which is used to treat osteoporosis in women.
Radius Health, Inc.
Radius Health, Inc. researches and develops drug therapies to treat osteoporosis. The company offers TYMLOS, which is a parathyroid hormone-related protein analog drug used to treat osteoporosis.
Looking for more information on this market?Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.
Browse Related Reports:
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at firstname.lastname@example.org.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190731005453/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Technavio Research
Copyright Business Wire 2019.
PUB: 07/31/2019 06:00 AM/DISC: 07/31/2019 06:01 AM